Erfindergemeinschaft UroPep GbR v. Eli Lilly and Company et al, No. 2:15-cv-01202 (E.D. Tex. Mar. 3, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court are the following motions: (1) Defendant Eli Lilly & Company’s Motion for Summary Judgment T hat the Claims of the ’124 Patent Are Anticipated (“Lilly’s Anticipation Motion”), Dkt. No. 172; (2) Defendant Eli Lilly & Company’s Motion for Summary Judgment of Indefiniteness (“Lilly’s Indefiniteness Motion”) , Dkt. No. 173; (3) Defendant Eli Lilly & Company’s Motion for Summary Judgment of Noninfringement and No Willful Inf ringement (“Lilly’s Noninfringement Motion”), Dkt. No.